fda d.i.s.c.o. burst edition: fda approval of adcetris (brentuximab vedotin) in combination with ...
Published 6 months ago • 27 plays • Length 3:01Download video MP4
Download video MP3
Similar videos
-
4:01
fda d.i.s.c.o. burst edition: fda approval of tibsovo (ivosidenib) in combination with azacitidin...
-
7:01
fda d.i.s.c.o. burst edition: fda approvals of rituxan (rituximab) plus chemotherapy for pediatri...
-
1:13
fda approval of brentuximab vedotin plus avd in classical hodgkin lymphoma
-
7:01
fda d.i.s.c.o. burst edition: fda approvals of verzenio (abemaciclib) for adjuvant treatment of a...
-
4:01
fda d.i.s.c.o. burst edition: fda approval yescarta (axicabtagene ciloleucel) for adult patients ...
-
4:01
fda d.i.s.c.o. burst edition: fda approves a new dosing regimen for asparaginase erwinia chrysant...
-
3:31
fda d.i.s.c.o. burst edition: fda approval of vidaza (azacitidine) for pediatric patients with ne...
-
17:57
dichloroacetate (dca) kills cancer & reverses warburg effect by inhibiting pdk
-
4:23
adcetris wedge sea hare
-
6:50
nivolumab-avd improved pfs versus brentuximab vedotin-avd in patients with advanced stage hl
-
5:31
fda d.i.s.c.o. burst edition: fda approval of orencia (abatacept) for prophylaxis of acute graft ...
-
0:41
dr. brammer on fda approval of brentuximab vedotin in ctcl
-
0:57
dr. flinn on fda approval of frontline brentuximab vedotin with avd in hodgkin lymphoma
-
8:01
fda d.i.s.c.o.: fda approval of cablivi for acquired thrombotic thrombocytopenic purpura
-
7:01
fda d.i.s.c.o. burst edition: fda approvals of tabrecta (capmatinib) for metastatic non-small cel...
-
6:01
fda d.i.s.c.o. burst edition: fda approvals of imbruvica (ibrutinib) for pediatric patients with ...
-
3:01
fda d.i.s.c.o. burst edition: yescarta (axicabtagene ciloleucel) for adult patients with relapsed...
-
8:31
fda d.i.s.c.o.: first biosimilar approval for the treatment of cancer
-
6:31
fda d.i.s.c.o.: fda approval of cemiplimab-rwlc for cutaneous squamous cell carcinoma
-
5:01
fda d.i.s.c.o.: a new treatment for acute myelogenous leukemia
-
6:01
fda d.i.s.c.o.: osimertinib for non-small cell lung cancer